Every material Form 8-K Vir Biotechnology filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vir Biotechnology granted Norgine Pharma UK Limited an exclusive license for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial reimbursement of EUR 55 million, is eligible for up to EUR 495 million in milestones, and will earn royalties on net sales in that territory, while the companies share ECLIPSE trial costs. The company says the agreement extends its current cash runway into the fourth quarter of 2027.
Initial reimbursement payment of EUR 55 million to Vir, with closing for certain non-US jurisdictions subject to regulatory approval
Eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales in the licensed territory
Norgine to contribute approximately 25% of go-forward external costs for the ECLIPSE 1, 2 and 3 trials
Vir retains commercial rights in the United States and other markets outside the Greater China Territory; company expects cash runway into Q4 2027
Vir Biotechnology reported third quarter 2025 results for the period ended September 30, 2025. Net loss narrowed to $163.1 million, or $1.17 per share, from $213.7 million, or $1.56 per share, a year earlier, mainly because license expenses were lower than in the prior-year quarter, but total revenues fell to $0.2 million from $2.4 million. The company said it had $810.7 million in cash, cash equivalents and investments and expects that to fund operations into mid-2027.
Net loss was $163.1 million, or $1.17 per share, versus $213.7 million, or $1.56 per share, in Q3 2024
Total revenues were $0.2 million versus $2.4 million in Q3 2024; R&D expenses were $151.5 million versus $195.2 million
Cash, cash equivalents and investments were $810.7 million at September 30, 2025, down about $81.4 million in the quarter; ECLIPSE 1 Phase 3 enrollment completed about two months early
Vir Biotechnology reported second-quarter 2025 results, with a net loss of $111.0 million, or $0.80 per share, compared with $138.4 million, or $1.02 per share, a year earlier. Revenue fell to $1.2 million from $3.1 million, and cash, cash equivalents and investments were $892.1 million at June 30, 2025, which the company says funds operations into mid-2027.
Net loss was $111.0 million ($0.80 per share) versus $138.4 million ($1.02 per share) in Q2 2024.
Total revenues were $1.2 million versus $3.1 million in Q2 2024.
Cash, cash equivalents and investments were $892.1 million at June 30, 2025, down about $127.7 million in the quarter, including $50.5 million of ECLIPSE milestone payments.
R&D expenses were $97.5 million versus $105.1 million, reflecting restructuring savings; the ECLIPSE registrational program in chronic hepatitis delta is fully underway.
Vir Biotechnology reported first quarter 2025 results, with total revenue of $3.0 million, down from $56.4 million a year earlier, mainly because $51.7 million of deferred revenue was recognized in Q1 2024. The net loss grew to $121.0 million, or $(0.88) per share, from $65.3 million, or $(0.48) per share, as research and development spending rose to $118.6 million. The company said its roughly $1.0 billion in cash and investments funds operations into mid-2027.
Total revenue was $3.0 million for Q1 2025, versus $56.4 million for Q1 2024.
Net loss was $121.0 million, or $(0.88) per share, versus $65.3 million, or $(0.48) per share, a year earlier.
R&D expense rose to $118.6 million, including a $30.0 million expense to Alnylam and the start of the ECLIPSE Phase 3 program.
Cash, cash equivalents and investments were approximately $1.02 billion at March 31, 2025, down about $75.6 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vir Biotechnology filing is on SEC EDGAR ↗. 8-K briefs of other companies →